Nevertheless, a prospective validation of the impact of survivin expression in anal carcinoma has to be performed on the basis of a clinical trial including a standardized protocol of immunohistochemical evaluation of the protein in pretreatment specimens. This evidence concerns the gene BIRC5 and anal carcinoma.